CytoMed Therapeutics Ltd
GDTC · XNASCIK 1873093fmd_03BRGKE9AFKV5DCNNFMK4P12XNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 6 periods
Latest annual · FY2025
Millions- Total revenues
- 0
- Net income
- (4)
- Free cash flow
- (4)
Daily close · GDTCIEX trades only
Nov 09, 2026 to Nov 09, 2026 · 1 sessions0.83 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- n/m
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
CytoMed Therapeutics Ltd (GDTC) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | SGD 324,387 | SGD 69,501 | +366.7% | 20-F 2026-03-31 · proof |
| Net income | -SGD 4 million | -SGD 2.5 million | 20-F 2026-03-31 · proof | |
| Cash from operating activities | -SGD 3.7 million | -SGD 2.7 million | 20-F 2026-03-31 · proof | |
| Free cash flow | -SGD 4.3 million | -SGD 4.1 million | 20-F 2026-03-31 · proof | |
| Total assets | SGD 8 million | SGD 10.1 million | -20.7% | 20-F 2026-03-31 · proof |
| Total liabilities | SGD 1.1 million | SGD 1 million | +10.5% | 20-F 2026-03-31 · proof |
| Cash and cash equivalents | SGD 2.1 million | SGD 4.7 million | -55.4% | 20-F 2026-03-31 · proof |
| Total debt | SGD 409,503 | SGD 431,960 | -5.2% | 20-F 2026-03-31 · proof |
- What was CytoMed Therapeutics Ltd (GDTC)'s revenue in fiscal 2025?
- CytoMed Therapeutics Ltd (GDTC) reported revenue of SGD 324,387 for fiscal 2025 (the year ended Dec 31, 2025), against SGD 69,501 the year before (+366.7%). Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What was CytoMed Therapeutics Ltd (GDTC)'s net income in fiscal 2025?
- CytoMed Therapeutics Ltd (GDTC) reported net income of -SGD 4 million for fiscal 2025 (the year ended Dec 31, 2025), against -SGD 2.5 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What was CytoMed Therapeutics Ltd (GDTC)'s cash from operating activities in fiscal 2025?
- CytoMed Therapeutics Ltd (GDTC) reported cash from operating activities of -SGD 3.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -SGD 2.7 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What was CytoMed Therapeutics Ltd (GDTC)'s free cash flow in fiscal 2025?
- CytoMed Therapeutics Ltd (GDTC) reported free cash flow of -SGD 4.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -SGD 4.1 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What are CytoMed Therapeutics Ltd (GDTC)'s total assets?
- As of Dec 31, 2025, CytoMed Therapeutics Ltd (GDTC) reported total assets of SGD 8 million, against SGD 10.1 million a year earlier (-20.7%). Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What are CytoMed Therapeutics Ltd (GDTC)'s total liabilities?
- As of Dec 31, 2025, CytoMed Therapeutics Ltd (GDTC) reported total liabilities of SGD 1.1 million, against SGD 1 million a year earlier (+10.5%). Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What are CytoMed Therapeutics Ltd (GDTC)'s cash and cash equivalents?
- As of Dec 31, 2025, CytoMed Therapeutics Ltd (GDTC) reported cash and cash equivalents of SGD 2.1 million, against SGD 4.7 million a year earlier (-55.4%). Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
- What is CytoMed Therapeutics Ltd (GDTC)'s total debt?
- As of Dec 31, 2025, CytoMed Therapeutics Ltd (GDTC) reported total debt of SGD 409,503, against SGD 431,960 a year earlier (-5.2%). Source: the 20-F filed with the SEC on Mar 31, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:GDTC&period_type=annual&limit=5"Information only, not investment advice.